Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 65(2), 87–108 (2015).
  MedlineGoogle Scholar
• 2 Abraham JA, Golubnitschaja O. Time for paradigm in hepatocellular carcinoma management: is an advanced approach by predictive, preventive and personalized medicine in horizon? Pers. Med. doi:10.2217/pme-2016-0013 (2016) (Manuscript in press). • Highlights current challenges in the overall management of hepatocellular carcinoma and justifies the paradigm change to predictive, preventive and personalized medical services.
  Google Scholar
• 3 Bargellini I, Battaglia V, Caramella D, Bortolozzi C. Imaging in hepatocellular carcinoma: radiologic assessment. In: An Information Technology Framework for Predictive, Preventive and Personalised Medicine: A Use-Case with Hepatocellular Carcinoma. Berliner L, Lemke HU (Eds). Springer International Publishing, Cham, Switzerland, 33–44 (2015).
  Google Scholar
• 4 Salem R, Lewandowski RJ, Kulik L et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140(2), 497–507 (2011).
  MedlineGoogle Scholar
• 5 Salem R, Gilbertsen M, Butt Z et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin. Gastroenterol. Hepatol. 11(10), 1358–1365 (2013).
  MedlineGoogle Scholar
• 6 Gramenzi A, Golfieri R, Mosconi C et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int. 35(3), 1036–1047 (2015).
  Medline CASGoogle Scholar
• 7 SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma (SARAH). https://clinicaltrials.gov/ct2/show/NCT01482442.
  Google Scholar
• 8 Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma. https://clinicaltrials.gov/ct2/show/NCT00846131.
  Google Scholar
• 9 Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer (SORAMIC). https://clinicaltrials.gov/ct2/show/NCT001126645.
  Google Scholar
• 10 Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) (SIRveNIB). https://clinicaltrials.gov/ct2/show/NCT01135056.
  Google Scholar
• 11 Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of Hepatocellular Carcinoma (HCC) (TRACE). https://clinicaltrials.gov/ct2/show/NCT01381211.
  Google Scholar
• 12 Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery. https://clinicaltrials.gov/ct2/show/NCT00956930.
  Google Scholar
• 13 Bhangoo MS, Karnani DR, Hein PN et al. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J. Gastrointest. Oncol. 6(5), 469–478 (2015).
  MedlineGoogle Scholar
• 14 Ashamalla H, Mattes MD. Radiation oncology in the treatment of hepatocellular carcinoma. In: An Information Technology Framework for Predictive, Preventive and Personalised Medicine: A Use-Case with Hepatocellular Carcinoma. Berliner L, Lemke HU (Eds). Springer International Publishing, Cham, Switzerland, 93–102 (2015).
  Google Scholar
• 15 Fernandez-Ros N, Inarrairaegui M, Paramo JA et al. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. Liver Int. 35(5), 1590–1596 (2015). •• Describes comprehensive molecular events during the postradioembolization period characteristic for hepatocellular carcinoma patients, demonstrates that molecular changes vary across different methodologies used and specifies molecular pathways that should be considered for targeted treatments.
  Medline CASGoogle Scholar
• 16 Golubnitschaja O, Cebioglu M, Yeghiazaryan K, Pieper C, Schild HH. “Molecular signature” in blood of liver cancer diagnosed patients as a criterion for optimal therapy modalities. EPMA J. 5(Suppl. 1), A38 (2014). •• Highlights benefits of minimally invasive diagnostic approaches and specifically of ‘molecular signature’ in patient stratification for personalization of treatment strategies in liver cancer.
  Google Scholar
• 17 Abraham JA, Golubnitschaja O. Predictive and prognostic biomarker panel for targeted application of radioembolisation improving individual outcomes in hepatocellular carcinoma. EPMA J. 7(Suppl. 1), A1 (2016). •• Provides important information for the most optimal set-up of predictive and prognostic biomarker panel which may sufficiently improve screening programs and individual outcomes in hepatocellular carcinoma.
  MedlineGoogle Scholar
• 18 Golubnitschaja O, Kinkorova J, Costigliola V. Predictive, Preventive and Personalised Medicine as the hardcore of “Horizon 2020”: EPMA position paper. EPMA J. 5(1), 6 (2014).
  MedlineGoogle Scholar
• 19 Ahmadzadehfar H, Sabet A, Biersack HJ. Radioembolization for the treatment of unresectable hepatocellular carcinoma. In: Hepatocellular Carcinoma – Future Outlook. Kaseb AO (Ed.). InTech, Rijeka, Croatia, 41–62 (2013).
  Google Scholar
• 20 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: role and perspectives. World J. Hepatol. 7(5), 738–752 (2015).
  MedlineGoogle Scholar
• 21 Lam MG, Abdelmaksoud MH, Chang DT et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 87(2), 323–329 (2013).
  MedlineGoogle Scholar
• 22 Gates VL, Singh N, Lewandowski RJ, Spies S, Salem R. Intraarterial Hepatic SPECT/CT Imaging Using 99mTc-Macroaggregated Albumin in Preparation for Radioembolization. J. Nucl. Med. 56(8), 1157–1162 (2015).
  Medline CASGoogle Scholar
• 23 Hipps D, Ausania F, Manas DM, Rose JD, French JJ. Selective interarterial radiation therapy (SIRT) in colorectal liver metastases: how do we monitor response? HPB Surg. 2013, 570808 (2013).
  Medline CASGoogle Scholar
• 24 Garin E, Rolland Y, Laffont S, Edeline J. Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur. J. Nucl. Med. Mol. Imaging 43(3), 559–575 (2016).
  Medline CASGoogle Scholar
• 25 Memon K, Lewandowski RJ, Riaz A, Salem R. Yttrium 90 microspheres for the treatment of hepatocellular carcinoma. In: Multidisciplinary Treatment of Hepatocellular Carcinoma. Vauthey J-N, Brouquet A (Eds). Springer Berlin Heidelberg, Germany, 207–224 (2013).
  Google Scholar
• 26 Earl TM, Chapman WC. Transplantation for hepatocellular carcinoma: the North American experience. In: Multidisciplinary Treatment of Hepatocellular Carcinoma. Vauthey J-N, Brouquet A (Eds). Springer Berlin Heidelberg, Germany, 145–164 (2013).
  Google Scholar
• 27 Schlachterman A, Craft WW, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J. Gastroenterol. 21(28), 8478–8491 (2015).
  MedlineGoogle Scholar
• 28 Golubnitschaja O, Watson ID, Topic E, Sandberg S, Ferrari M, Costigliola V. Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health care. EPMA J. 4(1), 12 (2013).
  MedlineGoogle Scholar
• 29 Golubnitschaja O, Yeghiazaryan K, Costigliola V et al. Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J. 4(1), 6 (2013).
  MedlineGoogle Scholar
• 30 Riaz A, Lewandowski RJ, Kulik LM et al. Complications following radioembolization with Yttrium-90 microspheres: a comprehensive literature review. J. Vasc. Interv. Radiol. 20(9), 1121–1130 (2009).
  MedlineGoogle Scholar
• 31 Gil-Alzugaray B, Chopitea A, Inarrairaegui M et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology 57(3), 1078–1087 (2013). •• Discusses the importance of changing the concepts of SIRT application for more personalized approaches, in order to improve individual outcomes.
  Medline CASGoogle Scholar
• 32 Sangro B, Gil-Alzugaray B, Rodriguez J et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 112(7), 1538–1546 (2008).
  MedlineGoogle Scholar
• 33 Cheng W, Xiao L, Ainiwaer A et al. Molecular responses of radiation-induced liver damage in rats. Mol. Med. Rep. 11(4), 2592–2600 (2015).
  Medline CASGoogle Scholar
• 34 Lau WY, Leung WT, Ho S et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial Yttrium-90 microspheres: a Phase I and II study. Br. J. Cancer 70(5), 994–999 (1994).
  Medline CASGoogle Scholar
• 35 Lau W-Y, Kennedy AS, Kim YH et al. Patient selection and activity planning guide for selective internal radiotherapy with Yttrium-90 resin microspheres. Int. J. Radiat. Oncol. Biol. Phys. 82(1), 401–407 (2012).
  MedlineGoogle Scholar
• 36 Garin E, Lenoir L, Rolland Y et al. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J. Nucl. Med. 53(2), 255–263 (2012).
  Medline CASGoogle Scholar
• 37 Mazzaferro V, Sposito C, Bhoori S et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a Phase 2 study. Hepatology 57(5), 1826–1837 (2013).
  Medline CASGoogle Scholar
• 38 Garin E, Rolland Y, Edeline J et al. Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis. J. Nucl. Med. 56(3), 339–346 (2015).
  Medline CASGoogle Scholar
• 39 Barnett GC, Kerns SL, Noble DJ, Dunning AM, West CM, Burnet NG. Incorporating genetic biomarkers into predictive models of normal tissue toxicity. Clin. Oncol. (R. Coll. Radiol.) 27(10), 579–587 (2015).
  Medline CASGoogle Scholar
• 40 Burnet NG, Wurm R, Nyman J, Peacock JH. Normal tissue radiosensitivity-how important is it? Clin. Oncol. (R. Coll. Radiol.) 8(1), 25–34 (1996).
  Medline CASGoogle Scholar
• 41 Wang B. Analyzing cell cycle checkpoints in response to ionizing radiation in mammalian cells. Methods Mol. Biol. 1170, 313–320 (2014).
  MedlineGoogle Scholar
• 42 Hein AL, Ouellette MM, Yan Y. Radiation-induced signaling pathways that promote cancer cell survival (review). Int. J. Oncol. 45(5), 1813–1819 (2014). •• Provides insights into molecular pathways negatively impacting outcomes after ionizing irradiation and suggests new molecular targets for precision medicine.
  Medline CASGoogle Scholar
• 43 Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15(7), 409–425 (2015). •• Provides insights into molecular mechanisms that underlie therapy resistance and tumor recurrence under irradiation and discusses the central role of microenvironment for individual outcomes.
  Medline CASGoogle Scholar
• 44 Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144(3), 512–527 (2013).
  MedlineGoogle Scholar
• 45 Persa E, Balogh A, Safrany G, Lumniczky K. The effect of ionizing radiation on regulatory T cells in health and disease. Cancer Lett. 368(2), 252–261 (2015).
  Medline CASGoogle Scholar
• 46 Huber SM, Butz L, Stegen B et al. Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol. 4, 212 (2013).
  MedlineGoogle Scholar
• 47 Lumniczky K, Safrany G. The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Lett. 356(1), 114–125 (2015).
  Medline CASGoogle Scholar
• 48 Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med. J. 50(5), 601–612 (2009).
  MedlineGoogle Scholar
• 49 Wu H, Zhao W, Liu S, Zheng J, Ji G, Xie Y. Pure transcatheter arterial chemoembolization therapy for intrahepatic tumors causes a shrink in pulmonary metastases of hepatocellular carcinoma. Int. J. Clin. Exp. Med. 8(1), 1035–1042 (2015).
  MedlineGoogle Scholar
• 50 Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin. Oncol. 39(4), 461–472 (2012).
  Medline CASGoogle Scholar
• 51 Scartozzi M, Faloppi L, Bianconi M et al. The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS ONE 7(3), e32653 (2012).
  Medline CASGoogle Scholar
• 52 Dayal R, Singh A, Pandey A, Mishra KP. Reactive oxygen species as mediator of tumor radiosensitivity. J. Cancer Res. Ther. 10(4), 811–818 (2014).
  MedlineGoogle Scholar
• 53 Kim W, Youn H, Kang C, Youn B. Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis 20(9), 1242–1252 (2015).
  Medline CASGoogle Scholar
• 54 Cichoz-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J. Gastroenterol. 20(25), 8082–8091 (2014).
  MedlineGoogle Scholar
• 55 Shin SM, Yang JH, Ki SH. Role of the Nrf2–ARE pathway in liver diseases. Oxid. Med. Cell Longev. 2013, 763257 (2013).
  MedlineGoogle Scholar
• 56 Carvajal-Yepes M, Himmelsbach K, Schaedler S et al. Hepatitis C virus impairs the induction of cytoprotective Nrf2 target genes by delocalization of small Maf proteins. J. Biol. Chem. 286(11), 8941–8951 (2011).
  Medline CASGoogle Scholar
• 57 Yazlovitskaya EM, Voziyan PA, Manavalan T, Yarbrough WG, Ivanova AV. Cellular oxidative stress response mediates radiosensitivity in Fus1-deficient mice. Cell Death Dis. 6, e1652 (2015).
  Medline CASGoogle Scholar
• 58 Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol. Pathol. 38(1), 96–109 (2010).
  Medline CASGoogle Scholar
• 59 Yang LY, Chen WL, Lin JW et al. Differential expression of antioxidant enzymes in various hepatocellular carcinoma cell lines. J. Cell Biochem. 96(3), 622–631 (2005).
  Medline CASGoogle Scholar
• 60 Mollbrink A, Jawad R, Vlamis-Gardikas A et al. Expression of thioredoxins and glutaredoxins in human hepatocellular carcinoma: correlation to cell proliferation, tumor size and metabolic syndrome. Int. J. Immunopathol. Pharmacol. 27(2), 169–183 (2014).
  Medline CASGoogle Scholar
• 61 Al-Shabrawey M, Smith S. Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers. EPMA J. 1(1), 56–72 (2010).
  MedlineGoogle Scholar
• 62 Yeghiazaryan K, Mamlouk S, Trog D et al. Irradiated breast cancer patients demonstrate subgroup-specific regularities in protein expression patterns of circulating leukocytes. Cancer Genomics Proteomics 4(6), 411–418 (2007).
  Medline CASGoogle Scholar
• 63 Trovato FM, Catalano D, Musumeci G, Trovato GM. 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics. EPMA J. 5(1), 21 (2014).
  MedlineGoogle Scholar
• 64 Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8(5), 292–301 (2011).
  Medline CASGoogle Scholar
• 65 Flamen P, Vanderlinden B, Delatte P et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys. Med. Biol. 53(22), 6591–6603 (2008).
  MedlineGoogle Scholar
• 66 Tu T, Budzinska MA, Maczurek AE et al. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int. J. Mol. Sci. 15(6), 9422–9458 (2014).
  Medline CASGoogle Scholar
• 67 Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9(6), 1957–1971 (2003).
  Medline CASGoogle Scholar
• 68 Wu XZ, Xie GR, Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 22(8), 1178–1182 (2007).
  Medline CASGoogle Scholar
• 69 Vanharanta S. A hypoxic ticket to the bone metastatic niche. Breast Cancer Res. 17, 122 (2015).
  MedlineGoogle Scholar
• 70 Wong CC, Tse AP, Huang YP et al. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology 60(5), 1645–1658 (2014).
  Medline CASGoogle Scholar
• 71 Cox TR, Bird D, Baker AM et al. LOX-mediated collagen crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res. 73(6), 1721–1732 (2013).
  Medline CASGoogle Scholar
• 72 Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21(3), 309–322 (2012).
  Medline CASGoogle Scholar
• 73 Clausson C-M, Grundberg I, Weibrecht I, Nilsson M, Söderberg O. Methods for analysis of the cancer microenvironment and their potential for disease prediction, monitoring and personalized treatments. EPMA J. 3(1), 7 (2012). •• Discusses the central role of tumor microenvironment for therapy outcomes and suggests innovative approaches for risk assessment and therapy monitoring.
  MedlineGoogle Scholar
• 74 Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin. Cancer Biol. 21(1), 35–43 (2011).
  Medline CASGoogle Scholar
• 75 Giannelli G, Villa E, Lahn M. Transforming growth factor-β as a therapeutic target in hepatocellular carcinoma. Cancer Res. 74(7), 1890–1894 (2014).
  Medline CASGoogle Scholar
• 76 Akyol G, Yilmaz G. Stem cell expression profile in hepatocellular carcinoma, small cell dysplasia, and cirrhosis. Stem Cell Transl. Investig. 1, e232 (2014).
  Google Scholar
• 77 Katoonizadeh A, Poustchi H. Adult hepatic progenitor cell niche: how it affects the progenitor cell fate. Middle East J. Dig. Dis. 6(2), 57–64 (2014).
  MedlineGoogle Scholar
• 78 Yamashita T, Ji J, Budhu A et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136(3), 1012–1024 (2009).
  Medline CASGoogle Scholar
• 79 Piao LS, Hur W, Kim TK et al. CD133⁺ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 315(2), 129–137 (2012).
  Medline CASGoogle Scholar
• 80 Lui SK, Vilchez V, Gedaly R. Liver cancer stem cells: a new paradigm for hepatocellular carcinoma treatment. J. Stem Cell Res. Ther. 5, 283 (2015).
  Google Scholar
• 81 Sainz B, Heeschen C. Standing out from the crowd: cancer stem cells in hepatocellular carcinoma. Cancer Cell 23(4), 431–433 (2013).
  Medline CASGoogle Scholar
• 82 Ma S. Biology and clinical implications of CD133⁺ liver cancer stem cells. Exp. Cell Res. 319(2), 126–132 (2013).
  Medline CASGoogle Scholar
• 83 Song YJ, Zhang SS, Guo XL et al. Autophagy contributes to the survival of CD133⁺ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Lett. 339(1), 70–81 (2013).
  Medline CASGoogle Scholar
• 84 Kohga K, Tatsumi T, Takehara T et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J. Hepatol. 52(6), 872–879 (2010).
  Medline CASGoogle Scholar
• 85 Romano M, De Francesco F, Pirozzi G et al. Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience 2(5), 443–456 (2015).
  MedlineGoogle Scholar
• 86 Kalathil S, Lugade AA, Miller A, Iyer R, Thanavala Y. Higher frequencies of GARP⁺ CTLA-4⁺ Foxp3⁺ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res. 73(8), 2435–2444 (2013).
  Medline CASGoogle Scholar
• 87 Shi F, Shi M, Zeng Z et al. PD-1 and PD-L1 upregulation promotes CD8⁺ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer 128(4), 887–896 (2011).
  Medline CASGoogle Scholar
• 88 Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8(3), 239–245 (2007).
  Medline CASGoogle Scholar
• 89 Bertino G, Demma S, Ardiri A et al. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res. Int. 2015, 731469 (2015).
  MedlineGoogle Scholar
• 90 Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
  Medline CASGoogle Scholar
• 91 Baban B, Liu JY, Zheng M, Lee J, Grochowska K, Mozaffari M. Programmed death-1in cancer stem cells may serve as a novel immunotherapy marker. EPMA J. 5(Suppl. 1), A115 (2014).
  Google Scholar
• 92 Muehlbauer M, Fleck M, Schütz C et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis. J. Hepatol. 45(4), 520–528 (2006).
  Medline CASGoogle Scholar
• 93 Kassel R, Cruise MW, Iezzoni JC, Taylor NA, Pruett TL, Hahn YS. Chronically inflamed livers up-regulate expression of inhibitory B7 family members. Hepatology 50(5), 1625–1637 (2009).
  MedlineGoogle Scholar
• 94 Yu MC, Chen CH, Liang X et al. Inhibition of T-cell responses by hepatic stellate cells via B7-H1-mediated T-cell apoptosis in mice. Hepatology 40(6), 1312–1321 (2004).
  Medline CASGoogle Scholar
• 95 Deng L, Liang H, Burnette B et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124(2), 687–695 (2014).
  Medline CASGoogle Scholar
• 96 Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J. Leukoc. Biol. 80(6), 1197–1213 (2006).
  Medline CASGoogle Scholar
• 97 Chen ZY, Wei W, Guo ZX et al. Using multiple cytokines to predict hepatocellular carcinoma recurrence in two patient cohorts. Br. J. Cancer 110(3), 733–740 (2014).
  Medline CASGoogle Scholar
• 98 Sheng T, Wang B, Wang SY et al. The relationship between serum interleukin-6 and the recurrence of hepatitis B virus related hepatocellular carcinoma after curative resection. Med. Baltim. 94(24), e941 (2015).
  Medline CASGoogle Scholar
• 99 Kose S, Ersan G, Tatar B, Adar P, Sengel BE. Evaluation of percutaneous liver biopsy complications in patients with chronic viral hepatitis. Eurasian J. Med. 47(3), 161–164 (2015).
  MedlineGoogle Scholar
• 100 Trovato FM, Tognarelli JM, Crossey MM, Catalano D, Taylor-Robinson SD, Trovato GM. Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers. World J. Hepatol. 7(26), 2664–2675 (2015).
  MedlineGoogle Scholar
• 101 Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH (NASH). https://clinicaltrials.gov/ct2/show/NCT01672879.
  Google Scholar
• 102 Yang ZF, Ngai P, Ho DW et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47(3), 919–928 (2008).
  Medline CASGoogle Scholar
• 103 Zhou G, Wilson G, George J, Qiao L. Targeting cancer stem cells as a therapeutic approach in liver cancer. Curr. Gene Ther. 15(2), 161–170 (2015).
  Medline CASGoogle Scholar
• 104 Northup PG, Caldwell SH. Coagulation in liver disease: a guide for the clinician. Clin. Gastroenterol. Hepatol. 11(9), 1064–1074 (2013).
  MedlineGoogle Scholar
• 105 Li F, Guo Z, Lizee G, Yu H, Wang H, Si T. Clinical prognostic value of CD4⁺ CD25⁺ FOXP3⁺ regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients. Clin. Chem. Lab. Med. 52(9), 1357–1365 (2014).
  Medline CASGoogle Scholar
• 106 Sangro B, Gomez-Martin C, de la Mata M et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59(1), 81–88 (2013).
  Medline CASGoogle Scholar
• 107 Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer. https://clinicaltrials.gov/ct2/show/NCT02311361.
  Google Scholar
• 108 A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer. https://clinicaltrials.gov/show/NCT01658878.
  Google Scholar
• 109 Nakamoto N, Cho H, Shaked A et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5(2), e1000313 (2009).
  MedlineGoogle Scholar
• 110 Hu R, Wang X, Zhan X. Multi-parameter systematic strategies for predictive, preventive and personalised medicine in cancer. EPMA J. 4(1), 2 (2013).
  MedlineGoogle Scholar
• 111 Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH). https://clinicaltrials.gov/ct2/show/NCT01672866.
  Google Scholar
• 112 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioblastoma. https://clinicaltrials.gov/ct2/show/NCT02423343.
  Google Scholar
• 113 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis (NASH-CX). https://clinicaltrials.gov/ct2/show/NCT02462967.
  Google Scholar